Immunovant (NASDAQ:IMVT) reported its Q2 earnings results on Friday, November 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.41) per share. This is a 17.14 percent decrease over losses of $(0.35) per share from the same period last year.
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Gainers
Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Immunovant's (NASDAQ:IMVT) short percent of float has risen 56.47% since its last report. The company recently reported that it has 2.66 million shares sold short, which is 6.29% of all regular shares that are available for trading.